AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Imugene’s HER-Vaxx and CHECKVacc were featured at the ESMO Congress this week
- Dr Joshua Tobias, Medical University of Vienna was the presenter of both HER-Vaxx presentations and Dr Jamie Rand from City of Hope presented on CHECKVacc
Imugene (ASX: IMU), a publicly traded immune-oncology company, has announced the inclusion of their B cell immunotherapy HER-Vaxx and CF33 oncolytic virotherapy CHECKVacc at the highly prestigious global oncology event, the European Society for Medical Oncology (ESMO) Congress, taking place this week in Madrid from October 20th to 24th, 2023.
The presentation titles featuring IMU’s products were –
Data source: Company update
Dr Joshua Tobias, Medical University of Vienna, presented both HER-Vaxx presentations.
Dr Jamie Rand, City of Hope, presented a poster session concerning CHECKVacc with the following title:
Data source: Company update
More
Let’s look into the highlights and conclusions of HER-Vaxx and CHECKVacc posters presented at the ESMO Congress.
Highlights of Poster 1536P (HER-Vaxx)
- HER-Vaxx vaccination reported statistically significant survival benefits when compared to chemotherapy alone.
- HER-Vaxx treatment showed robust anti-HER2 antibody responses.
- Patients with HER2-overexpressing gastric cancer, which were provided HER-Vaxx-based vaccination, validates the mechanism of action as they showed -
Data source: Company update
Highlights of poster 472P
Data source: Company update
Tumoral downregulation of HER2 expression and upregulation of PD-L1 have been associated with resistance and later metastasis development after the standard of care monoclonal antibody trastuzumab treatment.
Highlights of Poster Session #4581
Data source: Company update
The company informed that this trial is going on to evaluate tumor response, dose escalation and TME changes at higher dose levels and later time points.
IMU shares traded at AU$0.044 apiece at the time of writing on 24 October 2023.